ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2021 Operating Results
WALTHAM, Mass.--(BUSINESS WIRE)--Jul 15, 2021--
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 30, 2021 to discuss its second quarter operating results. Management will also provide a brief update on the business.
Conference Call Information
To access the live call by phone, dial (877) 621-5803; the conference ID is 1789134. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the call, a replay will be available at the same location.
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20210715005001/en/
CONTACT: INVESTOR RELATIONS AND MEDIA
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH HEALTH PHARMACEUTICAL ONCOLOGY
SOURCE: ImmunoGen Inc.
Copyright Business Wire 2021.
PUB: 07/15/2021 04:01 PM/DISC: 07/15/2021 04:02 PM